Literature DB >> 16267765

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.

Kristen M Marks1, Lydia M Petrovic, Andrew H Talal, Melissa P Murray, Roy M Gulick, Marshall J Glesby.   

Abstract

BACKGROUND: Hepatic steatosis, a common histological finding in hepatitis C virus (HCV)-infected patients, is associated with severity of fibrosis. The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized.
METHODS: To determine the prevalence and severity of steatosis, a single pathologist evaluated liver-biopsy samples from 106 patients coinfected with HIV and HCV but without hepatitis B infection (negative results for hepatitis B surface antigen) for findings associated with steatosis or steatohepatitis and viral hepatitis. Medical records were reviewed retrospectively to elucidate risk factors for steatosis.
RESULTS: Steatosis was present in 56% of biopsy samples, with moderate to severe grades in 9%. Severity of steatosis was associated with fibrosis (odds ratio [OR], 1.84 [95% confidence interval (CI), 1.06-3.20]; P=.03) but not with necroinflammation. In multivariate analysis, the severity of steatosis was associated with lower levels of high-density lipoprotein cholesterol (OR, 0.71 per 10-mg/dL increase [95% CI, 0.52-0.95]; P=.02), higher body-mass index (OR, 1.30 per kg/m2 increase [95% CI, 1.13-1.49]; P<.001), and the presence of lipodystrophy (OR, 3.82 [95% CI, 1.13-12.88]; P=.03). There was a trend toward an association between the severity of steatosis and fibrosis in multivariate analysis (OR, 1.69 [95% CI, 0.91-3.16]; P=.10).
CONCLUSIONS: In patients coinfected with HIV and HCV, hepatic steatosis is common and associated with more-advanced fibrosis. Lower levels of high-density lipoprotein cholesterol, higher body-mass index, and lipodystrophy are potentially modifiable risk factors associated with the severity of steatosis.

Entities:  

Mesh:

Year:  2005        PMID: 16267765     DOI: 10.1086/497608

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.

Authors:  Phyllis C Tien
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

Review 2.  Nonalcoholic fatty liver disease and HIV infection.

Authors:  Raphael B Merriman
Journal:  Curr HIV/AIDS Rep       Date:  2006-09       Impact factor: 5.071

Review 3.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

4.  HIV and liver disease forum: conference proceedings.

Authors:  Kenneth E Sherman; Marion Peters; Margaret James Koziel
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

5.  Nonalcoholic fatty liver disease among HIV-infected persons.

Authors:  Nancy Crum-Cianflone; Angelica Dilay; Gary Collins; Dean Asher; Richard Campin; Sheila Medina; Zach Goodman; Robin Parker; Alan Lifson; Thomas Capozza; Mary Bavaro; Braden Hale; Charles Hames
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

6.  Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.

Authors:  Richard K Sterling; Paula G Smith; Elizabeth M Brunt
Journal:  J Clin Gastroenterol       Date:  2013-02       Impact factor: 3.062

7.  Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Authors:  Kristen M Marks; Douglas Kitch; Raymond T Chung; Colleen Hadigan; Janet Andersen; Phyllis Tien; Annie Luetkemeyer; Beverly Alston-Smith; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

8.  Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.

Authors:  Monica A Konerman; Shruti H Mehta; Catherine G Sutcliffe; Trang Vu; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

9.  Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.

Authors:  V Borghi; L Bisi; L Manzini; A Cossarizza; C Mussini
Journal:  Infection       Date:  2012-12-09       Impact factor: 3.553

10.  Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals.

Authors:  Phyllis C Tien; Donald P Kotler; E Turner Overton; Cora E Lewis; David Rimland; Peter Bacchetti; Rebecca Scherzer; Barbara Gripshover
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.